FiREBOLT: A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (clinicaltrials.gov) - Oct 28, 2026 - P1 | N=340 | Recruiting | Sponsor: Eli Lilly and Company | N=241 ➔ 340
Enrollment change • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • FAP
|